Neumora Therapeutics, Inc.
NMRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001885522
In the last 90 days, Neumora Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $129.2M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Neumora Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 93
- +5 vs. Q1 2024
- Shares held
- 63.8M
- +11.1M (+21.1%) vs. Q1 2024
- Total value
- $627.4M
- −$98.0M (−13.5%) vs. Q1 2024
- New holders
- 24
- 42 more added
- Sold out
- 19
- 13 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NMRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 113 | $129.2M |
| Q1 2026 | 114 | $137.2M |
| Q4 2025 | 102 | $112.7M |
| Q3 2025 | 93 | $92.2M |
| Q2 2025 | 98 | $41.1M |
| Q1 2025 | 116 | $65.2M |
| Q4 2024 | 135 | $851.6M |
| Q3 2024 | 104 | $907.0M |
| Q2 2024 | 93 | $627.4M |
| Q1 2024 | 88 | $725.4M |
| Q4 2023 | 60 | $744.8M |
| Q3 2023 | 38 | $512.0M |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Neumora Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BIT Capital GmbH | 0 | $0 | 0.00% | −91,656−100.0% | Sold out |
| Nan Fung Group Holdings Ltd | 0 | $0 | 0.00% | −63,315−100.0% | Sold out |
| Wildcat Capital Management, LLC | 0 | $0 | 0.00% | −54,894−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −29,821−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −18,242−100.0% | Sold out |
| Wellington Management Group LLP | 0 | $0 | 0.00% | −14,187−100.0% | Sold out |
| Wealth Enhancement Advisory Services, LLC | 0 | $0 | 0.00% | −12,576−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −12,352−100.0% | Sold out |
| Oxford Asset Management LLP | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −7,331−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −921−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −5−100.0% | Sold out |